# Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Source: https://onco.cc/trials/nct03444844/  
OnCo record `nct03444844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ga-68 P16-093 PET/CT scan in prostate cancer, run by Five Eleven Pharma, Inc., active and no longer recruiting.

## Summary

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer is a phase 1/2 interventional study registered as NCT03444844 by Five Eleven Pharma, Inc., with 60 participants enrolled, started 2018-05-10 and due to reach its primary completion in 2020-10-27. Interventions recorded: Ga-68 P16-093 PET/CT scan.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03444844
- Phase: 1/2
- Setting: Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment
- Sponsor: Five Eleven Pharma, Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT03444844: https://clinicaltrials.gov/study/NCT03444844

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct03444844.json